The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.
Orazio Caffo
No relevant relationships to disclose
Lucia Fratino
No relevant relationships to disclose
Giovanni Lo Re
No relevant relationships to disclose
Umberto Basso
No relevant relationships to disclose
Alessandro D'Angelo
No relevant relationships to disclose
Maddalena Donini
No relevant relationships to disclose
Daniele Santini
No relevant relationships to disclose
Giuseppe Procopio
No relevant relationships to disclose
Francesco Massari
No relevant relationships to disclose
Donatello Gasparro
No relevant relationships to disclose
Francesco Verderame
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Caterina Messina
No relevant relationships to disclose
Roberto Iacovelli
No relevant relationships to disclose
Fable Zustovich
No relevant relationships to disclose
Giovanni Vicario
No relevant relationships to disclose
Anna Paola Fraccon
No relevant relationships to disclose
Vincenza Conteduca
No relevant relationships to disclose
Francesca Maines
No relevant relationships to disclose
Ugo De Giorgi
No relevant relationships to disclose